Latino Semaglutide Study
NCT05087342 on ClinicalTrials.gov · last registry update 2024-10-15
A small phase 3 — 119 participants, against a typical 424. The sponsor logged completion for 29 May 2024. Primary outcome, as filed: Assessment of weight loss. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Loma Linda University
- Sponsor type
- Other
- Enrollment
- 119
- Started
- 2022-12-13
- Primary completion
- 2024-05-29 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Assessment of weight loss.
Conditions studied
Obesity · Obesity; Drug · Overweight or Obesity · Weight Loss · Weight Loss Trajectory · Weight, Body
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.